CD30biAb-AATC for CD30+ Malignancies

Conditions:   Pediatric Cancer;   Hodgkin Disease;   CD30-Positive Diffuse Large B-Cell Lymphoma;   CD30+ Anaplastic Large Cell Lymphoma;   CD30+ Pleomorphic Large T-Cell Cutaneous Lymphoma;   CD30+ Immunoblastic Large T-Cell Cutaneous Lymphoma;   Neuroblastoma;   Germ Cell Tumor, Ext ragonadal;   Chondrosarcoma;   Leukemia;   Solid Tumor;   Lymphoma Intervention:   Drug: anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC) Sponsors:   Medical College of Wisconsin;   Midwest Athletes Against Childhood Cancer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials